Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdimmuneTPE:4142 -0.87%53 Cash Ratio is 1.33 as of Mar. 2026, which is 39% below its 10-year median of 2.18. GuruFocus rates TPE:4142 with a GF Score™ of 53/100 and a GF Value™ of NT$24.31 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,377 Biotechnology companies, Adimmune ranks worse than 67.32% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Adimmune Cash Ratio Related Terms
Adimmune Cash Ratio Historical Data
* Premium members only.
The historical data trend for Adimmune's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4142 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Adimmune's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adimmune Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adimmune's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Adimmune's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adimmune (TPE:4142) has a Cash Ratio of 1.33 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Adimmune and its competitors. This is 39% below median its historical median of 2.18. Over the past decade, Adimmune's Cash Ratio has ranged from 0.54 to 9.73. According to the industry distribution chart, Adimmune ranks #927 out of 1377 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Adimmune's Cash Ratio too high?
Adimmune's current Cash Ratio of 1.33 is 39% below median its 10-year median of 2.18. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 9.73. The Biotechnology industry median Cash Ratio is 2.96. Adimmune's value of 1.33 is 55.1% below this industry median. Based on the distribution chart, Adimmune ranks #927 out of 1377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adimmune has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #927 out of 1377 companies for Cash Ratio. This places Adimmune in the lower half of its industry. The industry median Cash Ratio is 2.96. Adimmune's value of 1.33 is 55.1% below this benchmark. Historically, Adimmune's own Cash Ratio has ranged from 0.54 to 9.73 over the past decade. While the company's 10-year median is 2.18 vs. the industry median of 2.96, Adimmune has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adimmune's current Cash Ratio of 1.33 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Adimmune and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adimmune's current Cash Ratio is 1.33, which is 39% below median its own 10-year median of 2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$24.31, compared to a current price of NT$17.15 — trading 29.5% below its estimated fair value. The current Cash Ratio is 1.33, which is 39% below median its 10-year median of 2.18 and 55.1% below the Biotechnology industry median of 2.96. Adimmune's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Cash Ratio is 1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$17.15 is trading 29.5% below its estimated GF Value™ of NT$24.31.
GuruFocus considers Adimmune to be Modestly Undervalued.
Key valuation signals for TPE:4142:
Cash Ratio: 1.33 (39% below median its 10-year median of 2.18)
GF Value™: NT$24.31 vs. price of NT$17.15 (29.5% below fair value)
Industry Position: 55.1% below the Biotechnology median (#927 of 1377)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
53GF Score
Get the complete analysis for TPE:4142
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
